Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Royalty Pharma
RPRX
|
$709M |
| 2 |
WIX.com
WIX
|
$282M |
| 3 |
Spotify
SPOT
|
$279M |
| 4 |
Mercado Libre
MELI
|
$249M |
| 5 |
Roblox
RBLX
|
$228M |
Top Sells
| 1 |
KE Holdings
BEKE
|
$298M |
| 2 |
CBRE Group
CBRE
|
$283M |
| 3 |
Tesla
TSLA
|
$275M |
| 4 |
Amazon
AMZN
|
$256M |
| 5 |
NVIDIA
NVDA
|
$237M |
Sector Composition
| 1 | Consumer Discretionary | 27.47% |
| 2 | Healthcare | 25.5% |
| 3 | Technology | 17.5% |
| 4 | Communication Services | 10.66% |
| 5 | Financials | 6.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Bristol-Myers Squibb
BMY
$94.5B
| $38K | ﹤0.01% |
488
+25
| +5% | +$1.95K |
|
|
NEWR
302
DELISTED
New Relic, Inc.
NEWR
| $37K | ﹤0.01% |
733
| – | – |
|
303
Halozyme
HALO
$8.81B
| $36K | ﹤0.01% |
815
+36
| +5% | +$1.59K |
|
304
Pure Storage
PSTG
$25.9B
| $34K | ﹤0.01% |
1,335
| – | – |
|
305
UnitedHealth
UNH
$289B
| $34K | ﹤0.01% |
67
| – | – |
|
306
Amkor Technology
AMKR
$6.14B
| $33K | ﹤0.01% |
1,976
+211
| +12% | +$3.52K |
|
307
Amdocs
DOX
$9.43B
| $32K | ﹤0.01% |
386
+21
| +6% | +$1.74K |
|
308
Inspire Medical Systems
INSP
$2.45B
| $32K | ﹤0.01% |
173
+19
| +12% | +$3.51K |
|
309
Costco
COST
$429B
| $30K | ﹤0.01% |
63
| – | – |
|
310
Regeneron Pharmaceuticals
REGN
$58.8B
| $30K | ﹤0.01% |
50
+4
| +9% | +$2.4K |
|
311
Tractor Supply
TSCO
$31.7B
| $30K | ﹤0.01% |
775
+95
| +14% | +$3.68K |
|
|
EH
312
EHang Holdings
EH
$1.17B
| $29K | ﹤0.01% |
3,105
+155
| +5% | +$1.45K |
|
313
ON Semiconductor
ON
$19.8B
| $29K | ﹤0.01% |
575
+75
| +15% | +$3.78K |
|
314
Humana
HUM
$37B
| $28K | ﹤0.01% |
60
+4
| +7% | +$1.87K |
|
315
W.W. Grainger
GWW
$47.6B
| $27K | ﹤0.01% |
60
+1
| +2% | +$450 |
|
|
GBT
316
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $27K | ﹤0.01% |
835
| – | – |
|
317
AstraZeneca
AZN
$251B
| $26K | ﹤0.01% |
400
| – | – |
|
318
Exelixis
EXEL
$10.1B
| $26K | ﹤0.01% |
1,230
+30
| +3% | +$634 |
|
319
Jazz Pharmaceuticals
JAZZ
$7.84B
| $26K | ﹤0.01% |
168
+3
| +2% | +$464 |
|
320
Pfizer
PFE
$139B
| $26K | ﹤0.01% |
500
| – | – |
|
321
Box
BOX
$4.79B
| $25K | ﹤0.01% |
979
| – | – |
|
322
Pool Corp
POOL
$12.3B
| $25K | ﹤0.01% |
70
| – | – |
|
323
Coherent
COHR
$15.4B
| $24K | ﹤0.01% |
477
+2
| +0.4% | +$101 |
|
324
Medifast
MED
$150M
| $24K | ﹤0.01% |
133
+13
| +11% | +$2.35K |
|
325
Monolithic Power Systems
MPWR
$41B
| $24K | ﹤0.01% |
63
| – | – |
|